U.S., Oct. 27 -- ClinicalTrials.gov registry received information related to the study (NCT07893665) titled 'PROfiles of FGF-19 Post-prandial Secretion in Older Adults With Frailty and Without Frailty' on Oct. 19.
Brief Summary: Fibroblast Growth Factor 19 (FGF-19) is an intestinal hormone secreted in the post-prandial state, whose primary role is to inhibit bile acid synthesis in the liver. It is expressed by the FXR (Farnesoid X receptor) nuclear receptor in the enterocytes of the ileum, which is activated by specific bile acids metabolized in the gut microbiota. It was demonstrated that treatment with FGF-19 induces myofiber hypertrophy in vitro and increases muscle strength and mass in mice model of sarcopenia. Sarcopenia and the commo...